Open an account

Regulus Therapeutics

RGLS · NASDAQ

Price unavailable right now.

No price history for this range.

About RGLS

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. The company is headquartered in San Diego, California and currently employs 34 full-time employees. The firm is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The firm is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, farabursen, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. The microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. The ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.

Employees
34
Headquarters
San Diego, California
Listed
Oct 4, 2012
Sector
Health Care
Industry
Biotechnology
Website
regulusrx.com

RGLS key statistics

This section is temporarily unavailable. Refresh to try again.

RGLS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 12.0% on average.

  1. Q2 FY23: reported -$0.37 per share against an estimate of -$0.4182
  2. Q3 FY23: reported -$0.40 per share against an estimate of -$0.4046
  3. Q4 FY23: reported -$0.40 per share against an estimate of -$0.4029
  4. Q1 FY24: reported -$0.29 per share against an estimate of -$0.227
  5. Q2 FY24: reported -$0.17 per share against an estimate of -$0.1496
  6. Q3 FY24: reported -$0.21 per share against an estimate of -$0.1734
  7. Q4 FY24: reported -$0.20 per share against an estimate of -$0.2142
  8. Q1 FY25: reported -$0.15 per share against an estimate of -$0.2499

RGLS news

  • Press releasePRNewswire

    Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, PPBI, COEP on Behalf of Shareholders

  • Press releaseBusiness Wire

    REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS

  • Avi Kapoor

    This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, SWTX on Behalf of Shareholders

  • Press releasePRNewswire

    SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc. - RGLS

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Avi Kapoor

    Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher

Similar companies

Companies in the same industry as Regulus Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.